Cover Image
市場調查報告書

市場預測:2017-2027年第一型糖尿病 (T1DM)的主要12個國家

Epiomic Epidemiology Series: Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027

出版商 Black Swan Analysis 商品編碼 486815
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
市場預測:2017-2027年第一型糖尿病 (T1DM)的主要12個國家 Epiomic Epidemiology Series: Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027
出版日期: 2017年03月01日 內容資訊: 英文 54 Pages
簡介

本報告提供全球主要12個國家中第一型糖尿病 (T1DM)的罹患情形調查,患病人數的變化與預測,各國家、並存症、嚴重度的明細,主要的標記抗體的陽性患者數的變化與預測,疾病概要,危險因素,疾病診斷與預後,主要的症狀和並存症等彙整資料。

調查對象國家

  • 巴西
  • 加拿大
  • 美國
  • 法國
  • 德國
  • 印度
  • 義大利
  • 日本
  • 俄羅斯
  • 西班牙
  • 英國
  • 美國

目錄

  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷
  • 各地區、民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要共生病症、特徵
  • 患者數的定量化技術
  • 第一型糖尿病的患病人數
  • 第一型糖尿病的特徵
    • T1DM患者的共生病症、後遺症
    • 患視網膜症病的T1DM患者數
    • T1DM抗體的陽性患者數
  • 簡稱一覽
  • 其他的出版物
  • 患者相關線上資料庫
  • 患者相關產品
  • 線上價格資料、平台
  • 參考文獻
  • 附錄
  • 圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: T1DM0010317

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets

Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas' ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to the lack of insulin. It occurs mainly in childhood and adolescents, however a rising number of latent autoimmune diabetes of adulthood (LADA) cases have been reported mainly due to a better understanding and diagnosis of the disease.

This report provides the current prevalent population for Type 1 Diabetes Mellitus across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Type 1 Diabetes Mellitus have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

There are many co-morbidities associated with Type 1 Diabetes Mellitus, including:

  • Chronic pancreatitis
  • Cystic fibrosis
  • Autoimmune disorders
  • Hyperglycaemia
  • Heart and blood vessel diseases (MI, Stroke, Atherosclerosis, Hypertension, Angina)
  • Neuropathy
  • Nephropathy (leading to CKD)
  • Ulcerations
  • Eye damage (retinopathy)
  • Foot damage
  • Ketoacidosis
  • Lower limb amputation
  • Skin/Mouth conditions
  • Pregnancy complications

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Type 1 Diabetes Mellitus market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Type 1 Diabetes Mellitus and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Type 1 Diabetes Mellitus prevalent population.
  • Identify sub-populations within Type 1 Diabetes Mellitus which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Type 1 Diabetes Mellitus patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line Prevalence for Type 1 Diabetes Mellitus
  • Features of Type 1 Diabetes Mellitus Patients
    • Comorbidities and Sequelae in T1DM Patients
    • T1DM patients with Retinopathy
    • Prevalence of T1DM defining antibodies
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Prevalence of Type 1 Diabetes Mellitus, total (000s)
  • Prevalence of Type 1 Diabetes Mellitus, males (000s)
  • Prevalence of Type 1 Diabetes Mellitus, females (000s)
  • T1DM patients by severity of Ketoacidosis, total (000s)
  • T1DM patients by kidney function, total (000s)
  • T1DM patients with Hypertension, total (000s)
  • Incidence of Lower Limb Amputations in T1DM patients, total (000s)
  • Incidence of Myocardial Infarction in T1DM patients, total (000s)
  • Incidence of Stroke in T1DM patients, total (000s)
  • Incidence of Angina in T1DM patients, total (000s)
  • T1DM patients with Peripheral Neuropathy, total (000s)
  • T1DM patients Diabetic Skin Conditions, total (000s)
  • T1DM patients Elevated HbA1c(>7.5%), total (000s)
  • T1DM patients with Coeliac Disease, total (000s)
  • T1DM patients with Retinopathy, total (000s)
  • T1DM patients with Retinopathy by Severity, total (000s)
  • T1DM patients with GADA antibodies, total (000s)
  • T1DM patients with ICA antibodies, total (000s)
  • T1DM patients with IA-2A antibodies, total (000s)
  • T1DM patients with IA-2BA antibodies, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • USA Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Canada Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Canada Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • France Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • France Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Germany Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Germany Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Italy Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Italy Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Spain Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Spain Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • UK Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • UK Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Japan Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Japan Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • India Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • India Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • China Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • China Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Russia Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Russia Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
Back to Top